{"id":4923,"date":"2024-09-24T12:53:00","date_gmt":"2024-09-24T16:53:00","guid":{"rendered":"https:\/\/herpescureadvocacy.com\/?p=4923"},"modified":"2026-03-24T22:40:25","modified_gmt":"2026-03-25T02:40:25","slug":"early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs","status":"publish","type":"post","link":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/","title":{"rendered":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs."},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Assembly Biosciences announced the most exciting results of the first phase 1a clinical trial of their most advanced helicase primase inhibitor, ABI-5366 (registered as clinical trial NCT06385327). The results exceeded expectations.  ABI-5366 was well tolerated and presented a pharmacological profile that supports potential once-weekly or even once-monthly dosages. The trial included four cohorts, dosed at 10, 30, 100, or 350 mg randomized 6:2 treatment to placebo, and a fifth cohort that evaluates any effects of food intake. The study was designed for a follow up of 70 days, but it has been extended now to 100 days, considering the long half-life. The safety results to date are up to 70 days for the lowest dosage and 8 days for the highest and slightly shorter for the pharmacodynamics studies. Half-life was about 20 days (oral dosage). No serious adverse effects have been observed, no clinical ECG events, no level 3-4 laboratory abnormalities, and no protocol defined stop criteria were reached in any patient.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The continuing Phase 1b clinical study has been announced in HSV-2 seropositive patients with recurrent genital infection. The trial will include multiple ascending weekly and monthly doses over a treatment interval of 29 days. Beyond continuing analyzing safety and pharmacological characteristics, this trial will also perform a preliminary analysis of antiviral therapeutic effects, including viral shedding and lesion recurrence and duration. This trial is recruiting. For more information, please refer to clinicaltrials.org (NCT06385327) or contact Assembly Biosciences directly (<a href=\"https:\/\/www.assemblybio.com\">https:\/\/www.assemblybio.com<\/a>; <a href=\"mailto:info@assemblybio.com\">info@assemblybio.com<\/a>)<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Assembly Biosciences is very excited about the results of the progress. CSO Dr. William Delaney expressed it as \u201cThe team here at Assembly Bio recognizes the urgent need for new treatments for people living with recurrent genital herpes. We are incredibly excited about these interim Phase 1a results for our investigational candidate ABI-5366 &#8211; these early data support the long-acting profile we are striving for and ABI-5366\u2019s progression to further clinical evaluation.\u00a0 We are currently enrolling the phase 1b part of the study as quickly as possible with a goal of sharing preliminary data on treatment efficacy in the first half of next year.&#8221;<\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n\n\n\n<div class=\"wp-block-media-text is-stacked-on-mobile\" style=\"border-width:1px;grid-template-columns:42% auto\"><figure class=\"wp-block-media-text__media\"><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" width=\"750\" height=\"750\" data-attachment-id=\"7143\" data-permalink=\"https:\/\/herpescureadvocacy.com\/?attachment_id=7143\" data-orig-file=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?fit=1080%2C1080&amp;ssl=1\" data-orig-size=\"1080,1080\" data-comments-opened=\"0\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"Document2\" data-image-description=\"\" data-image-caption=\"\" data-large-file=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?fit=750%2C750&amp;ssl=1\" src=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=750%2C750&#038;ssl=1\" alt=\"\" class=\"wp-image-7143 size-full\" srcset=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=1024%2C1024&amp;ssl=1 1024w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=300%2C300&amp;ssl=1 300w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=150%2C150&amp;ssl=1 150w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=768%2C768&amp;ssl=1 768w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=800%2C800&amp;ssl=1 800w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=600%2C600&amp;ssl=1 600w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=400%2C400&amp;ssl=1 400w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?resize=200%2C200&amp;ssl=1 200w, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/04\/Document2.png?w=1080&amp;ssl=1 1080w\" sizes=\"auto, (max-width: 750px) 100vw, 750px\" \/><\/figure><div class=\"wp-block-media-text__content\">\n<h6 class=\"wp-block-heading\"><strong><a href=\"https:\/\/herpescureadvocacy.com\/ways-to-give\/herpescureadvocacy.com\/donate\">Give Today and Join the Fight \u2192<\/a><\/strong><\/h6>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Every donation \u2013 whether $10 or $10,000 \u2013 moves us closer to a world where herpes is effectively treated and free from stigma.<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Questions about giving?<\/strong>\u00a0Contact us at\u00a0<a href=\"mailto:info@herpescureadvocacy.com\">info@herpescureadvocacy.com<\/a>\u00a0or 302-307-3560.<\/p>\n<\/div><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Assembly Biosciences announced the most exciting results of the first phase 1a clinical trial of their most advanced helicase primase inhibitor, ABI-5366 (registered as clinical trial NCT06385327). The results exceeded<a class=\"more-link\" href=\"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/\">Continue reading <span class=\"screen-reader-text\">&#8220;Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":205069572,"featured_media":4925,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"{title}\n\n{excerpt}\n\n{url}","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"_wpas_customize_per_network":false,"jetpack_post_was_ever_published":false},"categories":[2871573],"tags":[],"class_list":["post-4923","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-herpes-cure","entry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy\" \/>\n<meta property=\"og:description\" content=\"Assembly Biosciences announced the most exciting results of the first phase 1a clinical trial of their most advanced helicase primase inhibitor, ABI-5366 (registered as clinical trial NCT06385327). The results exceededContinue reading &quot;Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/\" \/>\n<meta property=\"og:site_name\" content=\"Herpes Cure Advocacy\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=100087212780212\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-24T16:53:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-25T02:40:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"512\" \/>\n\t<meta property=\"og:image:height\" content=\"98\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Patient Advocate\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@herpesadvocate\" \/>\n<meta name=\"twitter:site\" content=\"@herpesadvocate\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Patient Advocate\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/\"},\"author\":{\"name\":\"Patient Advocate\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/person\\\/5a8a408f85fcdaa526d3173c93216d14\"},\"headline\":\"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.\",\"datePublished\":\"2024-09-24T16:53:00+00:00\",\"dateModified\":\"2026-03-25T02:40:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/\"},\"wordCount\":353,\"commentCount\":1,\"publisher\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/download.jpg?fit=512%2C98&ssl=1\",\"articleSection\":[\"Herpes Cure Research\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/\",\"name\":\"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/download.jpg?fit=512%2C98&ssl=1\",\"datePublished\":\"2024-09-24T16:53:00+00:00\",\"dateModified\":\"2026-03-25T02:40:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/download.jpg?fit=512%2C98&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/download.jpg?fit=512%2C98&ssl=1\",\"width\":512,\"height\":98},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/2024\\\/09\\\/24\\\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#website\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\",\"name\":\"Herpes Cure Advocacy\",\"description\":\"Advocating for a cure for Herpes Simplex Virus.\",\"publisher\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/herpescureadvocacy.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#organization\",\"name\":\"Herpes Cure Advocacy\",\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/HCA-main-logo.png?fit=450%2C110&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/herpescureadvocacy.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/HCA-main-logo.png?fit=450%2C110&ssl=1\",\"width\":450,\"height\":110,\"caption\":\"Herpes Cure Advocacy\"},\"image\":{\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=100087212780212\",\"https:\\\/\\\/x.com\\\/herpesadvocate\",\"https:\\\/\\\/www.instagram.com\\\/herpesadvocate\",\"https:\\\/\\\/www.reddit.com\\\/r\\\/HerpesCureAdvocates\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/herpes-cure-advocacy\\\/\",\"https:\\\/\\\/www.tiktok.com\\\/@herpes.advocate?lang=en\",\"https:\\\/\\\/themighty.com\\\/groups\\\/herpescureadvocacy\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/herpescureadvocacy.com\\\/#\\\/schema\\\/person\\\/5a8a408f85fcdaa526d3173c93216d14\",\"name\":\"Patient Advocate\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g\",\"caption\":\"Patient Advocate\"},\"sameAs\":[\"http:\\\/\\\/herpescureadvocacy.com\"],\"url\":\"https:\\\/\\\/herpescureadvocacy.com\\\/author\\\/herpescureadvocacy\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/","og_locale":"en_US","og_type":"article","og_title":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy","og_description":"Assembly Biosciences announced the most exciting results of the first phase 1a clinical trial of their most advanced helicase primase inhibitor, ABI-5366 (registered as clinical trial NCT06385327). The results exceededContinue reading \"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.\"","og_url":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/","og_site_name":"Herpes Cure Advocacy","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=100087212780212","article_published_time":"2024-09-24T16:53:00+00:00","article_modified_time":"2026-03-25T02:40:25+00:00","og_image":[{"width":512,"height":98,"url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","type":"image\/jpeg"}],"author":"Patient Advocate","twitter_card":"summary_large_image","twitter_creator":"@herpesadvocate","twitter_site":"@herpesadvocate","twitter_misc":{"Written by":"Patient Advocate","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#article","isPartOf":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/"},"author":{"name":"Patient Advocate","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/person\/5a8a408f85fcdaa526d3173c93216d14"},"headline":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs.","datePublished":"2024-09-24T16:53:00+00:00","dateModified":"2026-03-25T02:40:25+00:00","mainEntityOfPage":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/"},"wordCount":353,"commentCount":1,"publisher":{"@id":"https:\/\/herpescureadvocacy.com\/#organization"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","articleSection":["Herpes Cure Research"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/","url":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/","name":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs. - Herpes Cure Advocacy","isPartOf":{"@id":"https:\/\/herpescureadvocacy.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#primaryimage"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","datePublished":"2024-09-24T16:53:00+00:00","dateModified":"2026-03-25T02:40:25+00:00","breadcrumb":{"@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#primaryimage","url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","contentUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","width":512,"height":98},{"@type":"BreadcrumbList","@id":"https:\/\/herpescureadvocacy.com\/2024\/09\/24\/early-phase-1a-clinical-trials-show-potential-for-long-acting-antiherpetic-drugs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/herpescureadvocacy.com\/"},{"@type":"ListItem","position":2,"name":"Early Phase 1a clinical trials show potential for long-acting antiherpetic drugs."}]},{"@type":"WebSite","@id":"https:\/\/herpescureadvocacy.com\/#website","url":"https:\/\/herpescureadvocacy.com\/","name":"Herpes Cure Advocacy","description":"Advocating for a cure for Herpes Simplex Virus.","publisher":{"@id":"https:\/\/herpescureadvocacy.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/herpescureadvocacy.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/herpescureadvocacy.com\/#organization","name":"Herpes Cure Advocacy","url":"https:\/\/herpescureadvocacy.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/03\/HCA-main-logo.png?fit=450%2C110&ssl=1","contentUrl":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/03\/HCA-main-logo.png?fit=450%2C110&ssl=1","width":450,"height":110,"caption":"Herpes Cure Advocacy"},"image":{"@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=100087212780212","https:\/\/x.com\/herpesadvocate","https:\/\/www.instagram.com\/herpesadvocate","https:\/\/www.reddit.com\/r\/HerpesCureAdvocates\/","https:\/\/www.linkedin.com\/company\/herpes-cure-advocacy\/","https:\/\/www.tiktok.com\/@herpes.advocate?lang=en","https:\/\/themighty.com\/groups\/herpescureadvocacy\/"]},{"@type":"Person","@id":"https:\/\/herpescureadvocacy.com\/#\/schema\/person\/5a8a408f85fcdaa526d3173c93216d14","name":"Patient Advocate","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/05ebcf007475af5bc907f5c9cdd152a398b8131b81e5609a9fdde2882fc76cfd?s=96&d=identicon&r=g","caption":"Patient Advocate"},"sameAs":["http:\/\/herpescureadvocacy.com"],"url":"https:\/\/herpescureadvocacy.com\/author\/herpescureadvocacy\/"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/11\/download.jpg?fit=512%2C98&ssl=1","jetpack_likes_enabled":true,"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/pcZX4e-1hp","jetpack-related-posts":[{"id":6628,"url":"https:\/\/herpescureadvocacy.com\/2025\/12\/09\/%f0%9f%9a%a8-big-news-in-herpes-research-promising-phase-1b-results-from-assembly-biosciences-%f0%9f%9a%a8\/","url_meta":{"origin":4923,"position":0},"title":"\ud83d\udea8 Big News in Herpes Research: Promising Phase 1b Results from Assembly Biosciences \ud83d\udea8","author":"Patient Advocate","date":"December 9, 2025","format":false,"excerpt":"There\u2019s major progress happening in the fight against HSV-2. Assembly Biosciences (ASMB) has reported very promising interim results from two Phase 1b clinical studies testing their new investigational treatments for recurrent genital herpes \u2014 ABI-1179 and ABI-5366. Here\u2019s what stood out: \ud83d\udca5 Key Clinical Results ABI-1179 (weekly oral dosing): 91%\u2026","rel":"","context":"In &quot;Herpes Cure Research&quot;","block_context":{"text":"Herpes Cure Research","link":"https:\/\/herpescureadvocacy.com\/category\/herpes-cure\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2025\/12\/img_2855-1.jpg?fit=1080%2C1080&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2025\/12\/img_2855-1.jpg?fit=1080%2C1080&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2025\/12\/img_2855-1.jpg?fit=1080%2C1080&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2025\/12\/img_2855-1.jpg?fit=1080%2C1080&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2025\/12\/img_2855-1.jpg?fit=1080%2C1080&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":2077,"url":"https:\/\/herpescureadvocacy.com\/2023\/03\/29\/promising-progress-in-clinical-trials-for-pritelivir\/","url_meta":{"origin":4923,"position":1},"title":"Promising Progress in clinical trials for Pritelivir","author":"Patient Advocate","date":"March 29, 2023","format":false,"excerpt":"Positive news abounds for the Aicuris team, and patients living with HSV, with the release of new results from their Phase three clinical trials for Pritelivir and initiation of a new clinical trial studying the use of Pritelivir in healthy patients. Pritelivir was found to be safe and well tolerated\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2023\/03\/29\/promising-progress-in-clinical-trials-for-pritelivir\/#comments"},"img":{"alt_text":"five oblong medication pills","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/03\/pexels-photo-593451.jpeg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":6655,"url":"https:\/\/herpescureadvocacy.com\/2026\/01\/06\/from-discovery-to-cure-understanding-the-complex-path-of-antiherpetic-drug-development\/","url_meta":{"origin":4923,"position":2},"title":"From Discovery to Cure: Understanding the Complex Path of Antiherpetic Drug Development","author":"Patient Advocate","date":"January 6, 2026","format":false,"excerpt":"We often hear headlines about breakthrough discoveries and promising new therapies for herpes \u2014 only to hear nothing more about them months or even years later. Why do so many promising antiherpetic drugs fail to reach patients? Why does drug development take so long, and where are the biggest bottlenecks?\u2026","rel":"","context":"In &quot;Herpes Cure Research&quot;","block_context":{"text":"Herpes Cure Research","link":"https:\/\/herpescureadvocacy.com\/category\/herpes-cure\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/01\/img_3101.jpg?fit=851%2C315&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/01\/img_3101.jpg?fit=851%2C315&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/01\/img_3101.jpg?fit=851%2C315&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2026\/01\/img_3101.jpg?fit=851%2C315&ssl=1&resize=700%2C400 2x"},"classes":[]},{"id":4168,"url":"https:\/\/herpescureadvocacy.com\/2024\/07\/24\/impressions-from-ihw-2024\/","url_meta":{"origin":4923,"position":3},"title":"Impressions from IHW 2024","author":"Patient Advocate","date":"July 24, 2024","format":false,"excerpt":"This year\u2019s conference highlighted several innovative studies focusing on interventions and antivirals targeting Herpes Simplex Viruses (HSV). Below, we summarize the key findings and their potential impacts on the treatment of HSV infections. Gene Editing Therapy for HSV One of the most promising developments presented was a gene editing therapy\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2024\/07\/24\/impressions-from-ihw-2024\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2024\/07\/Screenshot-2024-07-24-075548.png?resize=1050%2C600&ssl=1 3x"},"classes":[]},{"id":2277,"url":"https:\/\/herpescureadvocacy.com\/2023\/05\/10\/herpes-keratitis-cure-advances-to-phase-3-clinical-trials-in-china\/","url_meta":{"origin":4923,"position":4},"title":"Herpes Keratitis Cure advances to Phase 3 Clinical Trials in China","author":"Patient Advocate","date":"May 10, 2023","format":false,"excerpt":"BDGene Therapeutics is a Chinese biotech company based in Shanghai. BDgene now has approval to run Phase 3 trials (held in China) on their gene therapy cure for HSV-1 keratitis. The gene editing treatment for viral keratitis (BD111), developed based on BDmRNA delivery patent technology, has completed 3 human clinical\u2026","rel":"","context":"Similar post","block_context":{"text":"Similar post","link":""},"img":{"alt_text":"shallow focus photography of human eyes","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2023\/05\/pexels-photo-834783.jpeg?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":1861,"url":"https:\/\/herpescureadvocacy.com\/2022\/12\/30\/biontech-new-clinical-trial-for-herpes-vaccine-begins\/","url_meta":{"origin":4923,"position":5},"title":"BioNTech New Clinical Trial for Herpes Vaccine begins","author":"Patient Advocate","date":"December 30, 2022","format":false,"excerpt":"December 21 2022, BioNTech announced they had dosed the first clinical trial participant. This is the first-in-human study aims to evaluate the safety and immunogenicity of prophylactic herpes virus vaccine candidate BNT163. Company statement; \u201cWe aim to help address diseases with a high unmet medical need and of global health\u2026","rel":"","context":"With 1 comment","block_context":{"text":"With 1 comment","link":"https:\/\/herpescureadvocacy.com\/2022\/12\/30\/biontech-new-clinical-trial-for-herpes-vaccine-begins\/#comments"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/herpescureadvocacy.com\/wp-content\/uploads\/2022\/12\/pexels-photo-6804927.jpg?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"_links":{"self":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/4923","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/users\/205069572"}],"replies":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/comments?post=4923"}],"version-history":[{"count":2,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/4923\/revisions"}],"predecessor-version":[{"id":4926,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/posts\/4923\/revisions\/4926"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/media\/4925"}],"wp:attachment":[{"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/media?parent=4923"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/categories?post=4923"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/herpescureadvocacy.com\/wp-json\/wp\/v2\/tags?post=4923"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}